Research ArticleOpen AccessGoogle Scholar indexed
Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012
Internal Medicine Mayo Clinic Florida, Jacksonville, USA
Division of Hematology, Oncology Mayo Clinic Florida, Jacksonville, USA
- 1 Internal Medicine Mayo Clinic Florida, Jacksonville, USA
- 2 Division of Hematology, Oncology Mayo Clinic Florida, Jacksonville, USA
Open Journal of Urology·Volume 02 (2012)·Pages 210–215·Published 30 October 2012·DOI10.4236/oju.2012.223037
Copy link · social · email
Abstract
Castrate resistant metastatic prostate cancer remains a fatal disease. Through preclinical studies and clinical trials, a multitude of options have been made available to prolong the life of these patients, as well as improve quality of life. First line treatment options following tumor progression after androgen deprivation therapy include Provenge and docetaxel. Several options are available as second line treatment, including cabazitaxel, abiraterone, and enzalutamide. Many drugs currently being studied are very promising, such as alpharadin. Here we review treatment options for patients suffering from disease progression after androgen deprivation therapy, and offer a review of the current available options for the clinician.
KeywordsCastrateResistantProstateCancerTreatmentReview
- “Prostate Cancer Statistics,” 2012. http://www.cdc.gov/cancer/prostate/statistics
- V. T. DeVita, T. S. Lawrence and S. A. Rosenberg, “Cancer Principles and Practice of Oncology,” 2008.
- N. Howlader, “SEER Stat Fact Sheets: Prostate,” 2012. http://seer.cancer.gov/statfacts/html/prost.html
- K. Lassi, N. A. Dawson, “Emerging Therapies in Castrate-Resistant Prostate Cancer,” Current Opinion in Oncology, Vol. 21, No. 3, 2009, pp. 260-265. doi:10.1097/CCO.0b013e32832a1868
- R. M. Attar, C. H. Takimoto and M. M. Gottardis, “Castration-Resistant Prostate Cancer: Locking up the Molecular Escape Routes,” Clinical Cancer Research, Vol. 15, No. 10, 2009, pp. 3251-3255. doi:10.1158/1078-0432.CCR-08-1171
- D. R. Berthold, G. Pond, R. de Wit, et al., “Docetaxel plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival of Tax 327,” Journal of Clinical Oncology, Vol. 25, No. 18, 2007, pp. 242-245.
- E. J. Small, et al., “Placebo-Controlled Phase III Trial of Immunologic Therapy,” Journal of Clinical Oncology, Vol. 24, No. 19, 2006, pp. 3089-3093. doi:10.1200/JCO.2005.04.5252
- K. Phillip, C. Higano, et al., “Sipuleucel-T Immunotherapy for Castration-Resistant,” New England Journal of Medicine, Vol. 363, No. 5, 2010, pp. 411-422. doi:10.1056/NEJMoa1001294 PMid:20818862
- C. S. Higano, et al., “Integrated Data from 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy with Sipuleucel-T in Advanced Prostate Cancer,” Cancer, Vol. 115, No. 16, 2009, pp. 3670-3679. doi:10.1002/cncr.24429
- “United States Food and Drug Administration Package Insert,” 2012.
- R. M. Attar, C. H. Takimoto and M. M. Gottardis, “Castration-Resistant Prostate Cancer: Locking up the Molecular Escape Routes,” Clinical Cancer Research, Vol. 15, No. 10, 2009, pp. 3251-3255. doi:10.1158/1078-0432.CCR-08-1171
- J. S. de Bono, et al., “Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomised Open-Label Trial,” Lancet, Vol. 376, No. 9746, 2010, pp. 1147-1154. doi:10.1016/S0140-6736(10)61389-X
- “National Institutes of Health. Clinical Trials. 20,” 2012. http://clinicaltrials.gov/
- G. Attard, et al., “Selective Blockade of Androgenic Steroid Synthesis by Novel Lyase Inhibitors as a Therapeutic Strategy for Treating Metastatic Prostate Cancer,” British Journal of Urology International, Vol. 96, No. 9, 2005, pp. 1241-1246. doi:10.1111/j.1464-410X.2005.05821.x